the highest adherence to md category resulted in a significantly risk reduction for overall cancer mortality/incidence (cohort; rr: 0.90, 95% ci 0.86-0.95, p < 0.0001; i(2) = 55%), colorectal (cohort/case-control; rr: 0.86, 95% ci 0.80-0.93, p < 0.0001; i(2) = 62%], prostate (cohort/case-control; rr: 0.96, 95% ci 0.92-0.99, p = 0.03; i(2) = 0%) and aerodigestive cancer (cohort/case-control; rr: 0.44, 95% ci 0.26-0.77, p = 0.003; i(2) = 83%).